Surgery Partners, Inc.
SGRYHealthcareNASDAQMedical Care Facilities · Last scanned Sep 8, 2026
Scan Results
Daily timeframeSurgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. At a $1.87B market cap, Surgery Partners, Inc. ranks as a small-cap company within healthcare. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Market Cap
$1.87B
Beta
1.92
P/E (TTM)
—
P/E (Fwd)
22.73
EPS (TTM)
$-0.69
EPS (Fwd)
$0.63
ROE
2.3%
ROA
3.7%
Cash
$216.7M
Total Debt
$4.07B
Free CF
$183.6M
52W Change
-35.0%
Annual Financials
Cash vs Debt
Where SGRY stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SGRY finished 2.65% below its 150-day moving average ($14.36) and 5.28% below its 200-day moving average ($14.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SGRY overbought or oversold?
At the September 3, 2026 close, SGRY's RSI(14) was 38.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, SGRY has $216.7M in cash with $4.07B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $183.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 2.3%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $2.54B (2022) to $3.31B (2025), reflecting a 30% increase over the period.
With a beta above 1.5, SGRY tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Surgery Partners, Inc. and its sector.